Dual targeting with FLT3 CAR-T immunotherapy and FLT3 inhibitor (gilteritinib) are promising therapeutic strategies in FLT3-mutant AML and KMT2A-rearrangement ALL [85]. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.